{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "RNA-Seq : Questions médicales les plus fréquentes",
"headline": "RNA-Seq : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les RNA-Seq : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-03",
"dateModified": "2025-03-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "RNA-Seq"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Analyse de séquence d'ARN",
"url": "https://questionsmedicales.fr/mesh/D017423",
"about": {
"@type": "MedicalCondition",
"name": "Analyse de séquence d'ARN",
"code": {
"@type": "MedicalCode",
"code": "D017423",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E05.393.760.710"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "RNA-Seq",
"alternateName": "RNA-Seq",
"code": {
"@type": "MedicalCode",
"code": "D000081246",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Rency S Varghese",
"url": "https://questionsmedicales.fr/author/Rency%20S%20Varghese",
"affiliation": {
"@type": "Organization",
"name": "Genomics & Epigenomics Shared Resource, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA."
}
},
{
"@type": "Person",
"name": "Habtom W Ressom",
"url": "https://questionsmedicales.fr/author/Habtom%20W%20Ressom",
"affiliation": {
"@type": "Organization",
"name": "Genomics & Epigenomics Shared Resource, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. hwr@georgetown.edu."
}
},
{
"@type": "Person",
"name": "Qi Zhao",
"url": "https://questionsmedicales.fr/author/Qi%20Zhao",
"affiliation": {
"@type": "Organization",
"name": "Oujiang Laboratory, Zhejiang Lab for Regenerative Medicine, Vision and Brain Health, Wenzhou Medical University, Wenzhou, Zhejiang Province, China."
}
},
{
"@type": "Person",
"name": "Hongdi Cui",
"url": "https://questionsmedicales.fr/author/Hongdi%20Cui",
"affiliation": {
"@type": "Organization",
"name": "Oujiang Laboratory, Zhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province, China."
}
},
{
"@type": "Person",
"name": "Xu Yang",
"url": "https://questionsmedicales.fr/author/Xu%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Oujiang Laboratory, Zhejiang Provincial Key Laboratory of Medical Genetics, Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Accelerometry measures of physical activity and sedentary behavior: Associations with cognitive functioning in MS.",
"datePublished": "2023-08-28",
"url": "https://questionsmedicales.fr/article/37690438",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.msard.2023.104963"
}
},
{
"@type": "ScholarlyArticle",
"name": "Wrist-Worn Accelerometry, Aging, and Gait Speed in the Baltimore Longitudinal Study of Aging.",
"datePublished": "2022-10-13",
"url": "https://questionsmedicales.fr/article/36241170",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1123/japa.2022-0156"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adapting the Intensity Gradient for Use with Count-Based Accelerometry Data in Children and Adolescents.",
"datePublished": "2024-05-10",
"url": "https://questionsmedicales.fr/article/38793873",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/s24103019"
}
},
{
"@type": "ScholarlyArticle",
"name": "Physical Activity Assessed by Wrist and Thigh Worn Accelerometry and Associations with Cardiometabolic Health.",
"datePublished": "2023-08-23",
"url": "https://questionsmedicales.fr/article/37687813",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/s23177353"
}
},
{
"@type": "ScholarlyArticle",
"name": "Criterion validity of wrist accelerometry for assessing energy intake via the intake-balance technique.",
"datePublished": "2023-09-25",
"url": "https://questionsmedicales.fr/article/37749645",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12966-023-01515-0"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Techniques d'investigation",
"item": "https://questionsmedicales.fr/mesh/D008919"
},
{
"@type": "ListItem",
"position": 3,
"name": "Techniques génétiques",
"item": "https://questionsmedicales.fr/mesh/D005821"
},
{
"@type": "ListItem",
"position": 4,
"name": "Analyse de séquence",
"item": "https://questionsmedicales.fr/mesh/D017421"
},
{
"@type": "ListItem",
"position": 5,
"name": "Analyse de séquence d'ARN",
"item": "https://questionsmedicales.fr/mesh/D017423"
},
{
"@type": "ListItem",
"position": 6,
"name": "RNA-Seq",
"item": "https://questionsmedicales.fr/mesh/D000081246"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : RNA-Seq - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur RNA-Seq",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur RNA-Seq",
"description": "Comment l'RNA-Seq est-il utilisé dans le diagnostic ?\nQuels types de maladies peuvent être diagnostiqués par RNA-Seq ?\nL'RNA-Seq peut-il détecter des mutations ?\nQuelle est la précision de l'RNA-Seq pour le diagnostic ?\nL'RNA-Seq est-il standardisé pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D000081246?mesh_terms=Accelerometry&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur RNA-Seq",
"description": "Quels symptômes peuvent être analysés par RNA-Seq ?\nL'RNA-Seq peut-il identifier des biomarqueurs de symptômes ?\nPeut-on prédire des symptômes futurs avec RNA-Seq ?\nLes symptômes sont-ils liés à l'expression génique ?\nL'RNA-Seq peut-il aider à comprendre des symptômes complexes ?",
"url": "https://questionsmedicales.fr/mesh/D000081246?mesh_terms=Accelerometry&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur RNA-Seq",
"description": "L'RNA-Seq peut-il aider à la prévention des maladies ?\nComment l'RNA-Seq contribue-t-il à la recherche préventive ?\nPeut-on utiliser RNA-Seq pour le dépistage précoce ?\nQuels types de prévention sont possibles avec RNA-Seq ?\nL'RNA-Seq peut-il aider à la prévention des cancers ?",
"url": "https://questionsmedicales.fr/mesh/D000081246?mesh_terms=Accelerometry&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur RNA-Seq",
"description": "Comment l'RNA-Seq influence-t-il les traitements ?\nL'RNA-Seq peut-il guider le choix des médicaments ?\nQuels traitements peuvent être optimisés par RNA-Seq ?\nL'RNA-Seq peut-il aider à surveiller l'efficacité des traitements ?\nY a-t-il des traitements spécifiques basés sur RNA-Seq ?",
"url": "https://questionsmedicales.fr/mesh/D000081246?mesh_terms=Accelerometry&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur RNA-Seq",
"description": "Quelles complications peuvent être détectées par RNA-Seq ?\nL'RNA-Seq peut-il prédire des complications ?\nComment RNA-Seq aide-t-il à gérer les complications ?\nY a-t-il des complications spécifiques liées à RNA-Seq ?\nL'RNA-Seq peut-il aider à éviter des complications ?",
"url": "https://questionsmedicales.fr/mesh/D000081246?mesh_terms=Accelerometry&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur RNA-Seq",
"description": "Quels facteurs de risque peuvent être identifiés par RNA-Seq ?\nL'RNA-Seq peut-il révéler des risques pour des maladies spécifiques ?\nComment RNA-Seq aide-t-il à évaluer les facteurs de risque ?\nPeut-on utiliser RNA-Seq pour des études épidémiologiques ?\nL'RNA-Seq peut-il aider à identifier des risques environnementaux ?",
"url": "https://questionsmedicales.fr/mesh/D000081246?mesh_terms=Accelerometry&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment l'RNA-Seq est-il utilisé dans le diagnostic ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il permet d'identifier les niveaux d'expression des gènes et les mutations associées."
}
},
{
"@type": "Question",
"name": "Quels types de maladies peuvent être diagnostiqués par RNA-Seq ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé pour des cancers, des maladies génétiques et des infections virales."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq peut-il détecter des mutations ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut identifier des mutations dans les gènes exprimés, influençant le traitement."
}
},
{
"@type": "Question",
"name": "Quelle est la précision de l'RNA-Seq pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'RNA-Seq offre une haute précision pour quantifier l'expression génique."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq est-il standardisé pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il existe des protocoles standardisés, mais leur adoption varie selon les laboratoires."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent être analysés par RNA-Seq ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'RNA-Seq peut aider à comprendre les symptômes liés à des déséquilibres d'expression génique."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq peut-il identifier des biomarqueurs de symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut révéler des biomarqueurs associés à des symptômes spécifiques de maladies."
}
},
{
"@type": "Question",
"name": "Peut-on prédire des symptômes futurs avec RNA-Seq ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'RNA-Seq peut aider à prédire des symptômes en analysant les profils d'expression génique."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils liés à l'expression génique ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations dans l'expression génique peuvent être corrélées à des symptômes cliniques."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq peut-il aider à comprendre des symptômes complexes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il permet d'analyser des réseaux de gènes impliqués dans des symptômes complexes."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq peut-il aider à la prévention des maladies ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut identifier des facteurs de risque génétiques, permettant des mesures préventives."
}
},
{
"@type": "Question",
"name": "Comment l'RNA-Seq contribue-t-il à la recherche préventive ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il permet d'étudier les mécanismes moléculaires sous-jacents aux maladies pour mieux les prévenir."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser RNA-Seq pour le dépistage précoce ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être utilisé pour le dépistage précoce de certaines maladies génétiques."
}
},
{
"@type": "Question",
"name": "Quels types de prévention sont possibles avec RNA-Seq ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention ciblée et la surveillance des individus à risque sont possibles grâce à RNA-Seq."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq peut-il aider à la prévention des cancers ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut identifier des biomarqueurs de risque pour des interventions préventives."
}
},
{
"@type": "Question",
"name": "Comment l'RNA-Seq influence-t-il les traitements ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il permet de personnaliser les traitements en fonction des profils d'expression génique."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq peut-il guider le choix des médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il aide à identifier les médicaments les plus efficaces selon l'expression des gènes."
}
},
{
"@type": "Question",
"name": "Quels traitements peuvent être optimisés par RNA-Seq ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements du cancer et des maladies auto-immunes peuvent être optimisés grâce à RNA-Seq."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq peut-il aider à surveiller l'efficacité des traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il permet de suivre les changements d'expression génique en réponse aux traitements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques basés sur RNA-Seq ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées sont développées en fonction des résultats d'RNA-Seq pour certains cancers."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent être détectées par RNA-Seq ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut révéler des complications liées à des mutations génétiques ou à des déséquilibres d'expression."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq peut-il prédire des complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut aider à prédire des complications en analysant les profils d'expression génique."
}
},
{
"@type": "Question",
"name": "Comment RNA-Seq aide-t-il à gérer les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il permet d'adapter les traitements en fonction des complications identifiées par l'analyse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications spécifiques liées à RNA-Seq ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont généralement liées à l'interprétation des données plutôt qu'à la technique elle-même."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq peut-il aider à éviter des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en identifiant les risques, il peut contribuer à éviter certaines complications cliniques."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque peuvent être identifiés par RNA-Seq ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut identifier des facteurs génétiques et environnementaux associés à des maladies."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq peut-il révéler des risques pour des maladies spécifiques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut révéler des risques pour des maladies comme le cancer ou les maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment RNA-Seq aide-t-il à évaluer les facteurs de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il analyse l'expression des gènes pour déterminer les facteurs de risque potentiels."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser RNA-Seq pour des études épidémiologiques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est utilisé pour étudier les facteurs de risque dans des populations spécifiques."
}
},
{
"@type": "Question",
"name": "L'RNA-Seq peut-il aider à identifier des risques environnementaux ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut révéler comment les facteurs environnementaux influencent l'expression génique."
}
}
]
}
]
}
Cognitive dysfunction is a pervasive symptom of multiple sclerosis (MS). Correlational evidence on the relationships between physical activity, sedentary behavior, and cognition has been mixed and lim...
We analyzed baseline accelerometry and neuropsychological data (n = 80) from a randomized controlled trial of pedometer tracking. Using partial least squares regression (PLSR), we built three models t...
The latent component was significant for working memory/processing speed but was not significant for visual memory and verbal memory after Bonferroni correction. Working memory/processing speed was po...
These findings suggest that increasing overall energy expenditure through walking and MVPA, while decreasing prolonged sedentary time may positively benefit working memory/processing speed in people w...
This RCT #NCT03244696 was registered on Clinicaltrials.gov (https://www....
gov/ct2/show/NCT03244696)....
Wrist-worn accelerometry metrics are not well defined in older adults. Accelerometry data from 720 participants (mean age 70 years, 55% women) were summarized into (a) total activity counts per day, (...
The intensity gradient is a new cutpoint-free metric that was developed to quantify physical activity (PA) measured using accelerometers. This metric was developed for use with the ENMO (Euclidean nor...
Physical activity is increasingly being captured by accelerometers worn on different body locations. The aim of this study was to examine the associations between physical activity volume (average acc...
Intake-balance assessments measure energy intake (EI) by summing energy expenditure (EE) with concurrent change in energy storage (ΔES). Prior work has not examined the validity of such calculations w...
Healthy adults (n = 24) completed two 14-day measurement periods while wearing an ActiGraph accelerometer on the non-dominant wrist. During each period, criterion values of EI were determined based on...
Mean bias for the three best accelerometry-based methods ranged from -167 to 124 kcal/day, versus -104 to 134 kcal/day for the non-accelerometry-based methods. The same three accelerometry-based metho...
Accelerometry-based intake-balance methods have promise for advancing EI assessment, but ongoing refinement is necessary. We provide an R package to facilitate implementation and refinement of acceler...
Wrist-worn consumer sleep technologies (CST) that contain accelerometers (ACC) and photoplethysmography (PPG) are increasingly common and hold great potential to function as out-of-clinic (OOC) sleep ...
Remote health monitoring has become increasingly important, especially in aging populations. We aimed to identify tasks that are sensitive to age-related changes in balance during fully remote, at-hom...
Physical activity in paediatric and young adult patients suffering from inflammatory bowel disease (IBD) may play an important role in the overall health status. However, physical activity in these pa...
We recruited Danish patients with IBD aged 10-20 years in clinical remission and with a faecal calprotectin below 200 µg/mg. Physical activity was assessed using tri-axial wrist accelerometry over sev...
We included 61 patients with a median age of 17 years [Inter Quartile Range, IQR 14-19]. The total volume of activity expressed as average acceleration (ENMO) per day was 31.5 mg (95% CI 29.1-33.9). T...
We collected tri-axial accelerometry in young patients with IBD in clinical remission, and described their level of physical activity by the conventional ENMO measure. We found no statistically signif...
The Gait&Balance (G&B) App has produced valid and reliable measures of gait and balance in young healthy adults but has not been tested in older adults....
In healthy middle-to-older aged adults, are G&B App measurements sensitive to age, valid against clinical and kinematic measures, and reliable?...
Healthy participants (n = 34, 14 male, 42-94 years) completed the G&B App protocol three times within a single session. 3D kinematics were collected concurrently. Clinical balance measures were collec...
During quiet stance on a compliant surface, the G&B App was sensitive to age-related differences not detectable with the mCTSIB. During walking tasks, there was adequate convergent validity between th...
The G&B App was sensitive to age-related differences in balance not detectable with clinical measurement. It provides valid and reliable measures of postural stability, step length, step time, and per...
The aim of this study was to compare energy expenditure (EE) predicted by accelerometery (EE...
Twenty-four participants (12 with stroke and 12 healthy controls) performed a six-minute walk test (6MWT) during which EE...
The median EE...
The accuracy of the predicted EE, based on the accelerometer and the equations proposed by Bouten et al., was low in individuals with hemiparesis and impaired gait. This combination (sensor and Bouten...